BMRN Valuation

BioMarin Pharmaceutical Inc

Add to Watchlist

Advanced Chart

53.940

-0.42(-0.773%)1D

Overview
Forecast
Valuation
Earnings

BMRN Relative Valuation

BMRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMRN is overvalued; if below, it's undervalued.

Historical Valuation

BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.37 is considered Undervalued compared with the five-year average of 43.22. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 81.23 to 255.95 according to relative valuation methord. Compared to the current price of 53.94 USD , BioMarin Pharmaceutical Inc is Undervalued By 33.59%.

Relative Value

Fair Zone

81.23-255.95

Current Price：53.94

33.59%

Undervalued

12.37

Trailing

Forward

10.05

EV/EBITDA

BioMarin Pharmaceutical Inc. (BMRN) has a current EV/EBITDA of 10.05. The 5-year average EV/EBITDA is 75.27. The thresholds are as follows: Strongly Undervalued below -167.10, Undervalued between -167.10 and -45.92, Fairly Valued between 196.46 and -45.92, Overvalued between 196.46 and 317.64, and Strongly Overvalued above 317.64. The current Forward EV/EBITDA of 10.05 falls within the Historic Trend Line -Fairly Valued range.

11.93

EV/EBIT

BioMarin Pharmaceutical Inc. (BMRN) has a current EV/EBIT of 11.93. The 5-year average EV/EBIT is -3.06. The thresholds are as follows: Strongly Undervalued below -216.74, Undervalued between -216.74 and -109.90, Fairly Valued between 103.78 and -109.90, Overvalued between 103.78 and 210.62, and Strongly Overvalued above 210.62. The current Forward EV/EBIT of 11.93 falls within the Historic Trend Line -Fairly Valued range.

3.19

BioMarin Pharmaceutical Inc. (BMRN) has a current PS of 3.19. The 5-year average PS is 6.43. The thresholds are as follows: Strongly Undervalued below 3.39, Undervalued between 3.39 and 4.91, Fairly Valued between 7.95 and 4.91, Overvalued between 7.95 and 9.48, and Strongly Overvalued above 9.48. The current Forward PS of 3.19 falls within the Strongly Undervalued range.

8.75

P/OCF

BioMarin Pharmaceutical Inc. (BMRN) has a current P/OCF of 8.75. The 5-year average P/OCF is 38.28. The thresholds are as follows: Strongly Undervalued below -35.02, Undervalued between -35.02 and 1.63, Fairly Valued between 74.93 and 1.63, Overvalued between 74.93 and 111.58, and Strongly Overvalued above 111.58. The current Forward P/OCF of 8.75 falls within the Historic Trend Line -Fairly Valued range.

13.53

P/FCF

BioMarin Pharmaceutical Inc. (BMRN) has a current P/FCF of 13.53. The 5-year average P/FCF is 35.45. The thresholds are as follows: Strongly Undervalued below 7.68, Undervalued between 7.68 and 21.56, Fairly Valued between 49.33 and 21.56, Overvalued between 49.33 and 63.22, and Strongly Overvalued above 63.22. The current Forward P/FCF of 13.53 falls within the Undervalued range.

BioMarin Pharmaceutical Inc (BMRN) has a current Price-to-Book (P/B) ratio of 1.72. Compared to its 3-year average P/B ratio of 3.08 , the current P/B ratio is approximately -44.23% higher. Relative to its 5-year average P/B ratio of 3.27, the current P/B ratio is about -47.38% higher. BioMarin Pharmaceutical Inc (BMRN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.26% , the current FCF yield is about -100.00% lower.

1.72

P/B

Median3y

3.08

Median5y

3.27

6.66

FCF Yield

Median3y

1.70

Median5y

1.26

Competitors Valuation Multiple

The average P/S ratio for BMRN's competitors is , providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 15.92%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BMRN.O

BioMarin Pharmaceutical Inc

Elanco Animal Health Inc

Halozyme Therapeutics Inc

Performance Decomposition

Market capitalization of BMRN decreased by 23.26% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 15.05 to 29.14.

The secondary factor is the Revenue Growth, contributed 15.92%to the performance.

Overall, the performance of BMRN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

15.92%

712.03M → 825.41M

Revenue Growth

93.62%

15.05 → 29.14

Margin Expansion

-132.80%

-48.38 → 15.87

P/E Change

-23.26%